Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
在正在进行的鲁索替尼治疗中,加用纳维托克治疗进展或疗效欠佳的骨髓纤维化患者:II期安全性和有效性研究
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.02188
Harrison, Claire N; Garcia, Jacqueline S; Somervaille, Tim C P; Foran, James M; Verstovsek, Srdan; Jamieson, Catriona; Mesa, Ruben; Ritchie, Ellen K; Tantravahi, Srinivas K; Vachhani, Pankit; O'Connell, Casey L; Komrokji, Rami S; Harb, Jason; Hutti, Jessica E; Holes, Leanne; Masud, Abdullah A; Nuthalapati, Silpa; Potluri, Jalaja; Pemmaraju, Naveen